Cindy Sander
Overview
Explore the profile of Cindy Sander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
3332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karapetyan L, Li A, Vargas De Stefano D, Abushukair H, Al-Bzour A, Knight A, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39537211
Background: While the prognostic role of tertiary lymphoid structures (TLS) has been well studied in solid cancers, the prevalence and impact of immature precursor lymphoid structures known as lymphoid aggregates...
2.
Cillo A, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al.
Cell
. 2024 Aug;
187(16):4373-4388.e15.
PMID: 39121849
Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo...
3.
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura C, Sander C, et al.
Cancer Immunol Res
. 2024 Jul;
12(10):1421-1437.
PMID: 38949179
Cytotoxic CD8+ T lymphocyte (CTL) recognition of non-mutated tumor-associated antigens (TAA), present on cancer cells and also in healthy tissues, is an important element of cancer immunity, but the mechanism...
4.
Augustin R, Newman S, Li A, Joy M, Lyons M, Pham M, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37857525
Acral melanoma (AM) has distinct characteristics as compared with cutaneous melanoma and exhibits poor response to immune checkpoint inhibitors (ICIs). Tumor-intrinsic mechanisms of immune exclusion have been identified in many...
5.
Augustin R, Newman S, Li A, Joy M, Lyons M, Pham M, et al.
bioRxiv
. 2023 Sep;
PMID: 37662409
Background: Acral melanoma (AM) has distinct characteristics as compared to cutaneous melanoma and exhibits poor response to immune checkpoint inhibitors (ICI). Tumor-intrinsic mechanisms of immune exclusion have been identified in...
6.
Karapetyan L, Abushukair H, Li A, Knight A, Nedal Al Bzour A, MacFawn I, et al.
Front Immunol
. 2023 Jul;
14:1171978.
PMID: 37435077
Background: Proinflammatory chemokines/cytokines support development and maturation of tertiary lymphoid structures (TLS) within the tumor microenvironment (TME). In the current study, we sought to investigate the prognostic value of TLS-associated...
7.
Augustin R, Huang Z, Ding F, Zhai S, McArdle J, Santisi A, et al.
Front Oncol
. 2023 Jul;
13:1075823.
PMID: 37397389
Background: Pre-clinical studies have shown that metformin reduces intratumoral hypoxia, improves T-cell function, and increases sensitivity to PD-1 blockade, and metformin exposure has been associated with improved clinical outcomes in...
8.
Maguire W, Haley P, Dietz C, Hoffelder M, Brandt C, Joyce R, et al.
JID Innov
. 2023 Mar;
3(2):100181.
PMID: 36960318
The documentation of the change in the number and appearance of pigmented cutaneous lesions over time is critical to the early detection of skin cancers and may provide preliminary signals...
9.
Chun-On P, Hinchie A, Beale H, Gil Silva A, Rush E, Sander C, et al.
Science
. 2022 Nov;
378(6620):664-668.
PMID: 36356143
Overcoming replicative senescence is an essential step during oncogenesis, and the reactivation of through promoter mutations is a common mechanism. promoter mutations are acquired in about 75% of melanomas but...
10.
Karapetyan L, Gooding W, Li A, Yang X, Knight A, Abushukair H, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291758
We sought to develop a sentinel lymph node gene expression signature score predictive of disease recurrence in patients with cutaneous melanoma. Gene expression profiling was performed on SLN biopsies using...